Clinical Study

A Phase II Single-Arm Trial To Investigate Tepotinib In Stage IIIb/Iv Adenocarcinoma Of The Lung With Met Exon 14 (Metex14) Skipping Alterations After Failure Of At Least One Prior Active Therapy, Including A Platinum-Doublet-Containing Regimen

Posted Date: Feb 18, 2017

  • Investigator: John Morris
  • Co-Investigator: Andrea Collins
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Drug

The purpose of this study is to learn how effective the study drug, tepotinib, is at stopping the growth and spread of lung cancer that did not respond to previous treatment with a specific type of chemotherapy. This study will also measure the safety of

Criteria:

To Be Eligible To Participate, Study Participants Must Have Adenocarcinoma Of The Lung Which Has Been Previously Treated (Including Chemotherapy) But The Cancer Did Not Respond To The Treatment. This Type Of Lung Cancer Is Associated With A Specific Chang

Keywords:

Lung Cancer, Ms200095-0022, Lung, Cancer, Phase Ii

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.